Nov. 5, 2024 —Penumbra, Inc. recently announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra’s computer assisted vacuum thrombectomy (CAVT) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications compared to other treatment options. Additionally, in-hospital mortality was low with CAVT, with no significant difference between treatment options. The late-breaking study was presented this week at the Vascular Interventional Advances (VIVA) 2024 Conference.
“This first-of-a-kind analysis demonstrates that patients treated with CAVT utilized fewer hospital resources,” said Parag J. Patel, M.D., M.S., FSIR, who presented the data and is an interventional radiologist at Froedtert Hospital in Milwaukee, WI. “These findings, as well as recent studies which show CAVT’s positive impact on patient outcomes, strongly showcase the significant benefits of CAVT over other treatment options for PE. ”
The retrospective study used the Vizient Clinical Data Base to identify 2,060 adult inpatients with intermediate-risk PE. This rigorous 1:1 propensity score matched analysis included resource use and health outcomes among patients in the U.S. treated with Penumbra’s Lightning Flash or Lightning 12 technology compared to patients in the U.S. treated with anticoagulation, catheter directed thrombolysis or other mechanical thrombectomy devices.
When compared to other modalities studied, the data showed that CAVT resulted in:
- 25-35 percent shorter total hospital length of stay
- 25-30 percent higher average rate of patients discharged home
- 2-3 times fewer average composite complications
“Now with this study, the findings suggest that by increasing patient access to advanced therapies like CAVT, it can also have an important, positive impact on hospital systems by greatly reducing resource utilization versus other modalities, therefore decreasing the overall cost to the healthcare system,” said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra
In the study, CAVT was associated with improvement in contribution margin relative to anticoagulation alone. An example given was that if 10 percent more patients are treated with CAVT, hospitals could see up to a 75 percent gain in profitable contribution margin, representing thousands of dollars more per patient compared to treatment with anticoagulation alone. This data was presented separately in a symposium during the VIVA 2024 Conference.
For more information, visit www.penumbrainc.com
September 24, 2024 
